Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)

Market Cap	37.73B
Revenue (ttm)	6.30B
Net Income (ttm)	1.46B
Shares Out	1.98B
EPS (ttm)	0.73
PE Ratio	26.13
Forward PE	25.07
Dividend	0.15 (0.79%)
Ex-Dividend Date	Sep 25, 2025

Volume	11,067,912
Average Volume	11,269,753
Open	19.17
Previous Close	19.20
Day's Range	19.02 - 19.19
52-Week Range	18.86 - 27.60
Beta	0.36
RSI	35.61
Earnings Date	Oct 24, 2025

About SHA:600161

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for inje...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1966
• Employees: 5,298
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600161

Financial Performance

In 2024, SHA:600161's revenue was 6.03 billion, an increase of 16.44% compared to the previous year's 5.18 billion. Earnings were 1.55 billion, an increase of 39.58%.